The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Glycomul S     [2-[(2R,3S,4R)-3,4- dihydroxyoxolan-2-yl]-2...

Synonyms: Liposorb S, Sorbitan 0, Sorbitan C, Drewsorb 60, Crill 3, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Armotan MS


High impact information on Armotan MS

  • There was a slight reduction in the IC50 against the resistant cell line when the drug was encapsulated in Span 60 niosomes in comparison to the drug in solution [1].
  • Doxorubicin niosomes (10 mg kg-1 doxorubicin) prepared from sorbitan monostearate (Span 60), cholesterol and choleth-24 (a 24 oxyethylene cholesteryl ether) in the molar ratio 45:45:10 were administered intravenously to female NMRI mice bearing the MAC 15A subcutaneously implanted tumour [5].
  • The results indicate that the Span 60 is the most ideal surfactant among four kinds of Span. Furthermore, the release studies of colchicine and 5-fluorouracil (5-FU) in vitro from niosomes exhibited a prolonged release profile as studied over a period of 24 h [6].
  • The particle sizes of Span 40 niosomes and Span 60 niosomes were 242.5 +/- 20.5 nm and 259.7 +/- 33.8 nm, respectively [7].

Associations of Armotan MS with other chemical compounds


  1. The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. Uchegbu, I.F., Double, J.A., Kelland, L.R., Turton, J.A., Florence, A.T. Journal of drug targeting. (1996) [Pubmed]
  2. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. Jain, S., Vyas, S.P. Journal of liposome research (2006) [Pubmed]
  3. Long-term toxicity study of sorbitan monostearate (Span 60) in mice. Hendy, R.J., Butterworth, K.R., Gaunt, I.F., Kiss, I.S., Grasso, P. Food and cosmetics toxicology. (1978) [Pubmed]
  4. Characterization of de-emulsification capabilities of a Micrococcus species. Das, M. Bioresour. Technol. (2001) [Pubmed]
  5. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Uchegbu, I.F., Double, J.A., Turton, J.A., Florence, A.T. Pharm. Res. (1995) [Pubmed]
  6. Studies on a high encapsulation of colchicine by a niosome system. Hao, Y., Zhao, F., Li, N., Yang, Y., Li, K. International journal of pharmaceutics. (2002) [Pubmed]
  7. Niosomes with sorbitan monoester as a carrier for vaginal delivery of insulin: studies in rats. Ning, M., Guo, Y., Pan, H., Yu, H., Gu, Z. Drug delivery. (2005) [Pubmed]
  8. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Agarwal, R., Katare, O.P., Vyas, S.P. International journal of pharmaceutics. (2001) [Pubmed]
WikiGenes - Universities